BidaskClub upgraded shares of WAVE Life Sciences (NASDAQ:WVE) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning.
A number of other brokerages have also issued reports on WVE. Mizuho set a $34.00 target price on shares of WAVE Life Sciences and gave the company a buy rating in a research note on Friday, August 18th. Jefferies Group reissued a buy rating and set a $40.00 target price (down previously from $42.00) on shares of WAVE Life Sciences in a research note on Thursday, August 10th. Leerink Swann reissued an outperform rating and set a $53.00 target price (up previously from $42.00) on shares of WAVE Life Sciences in a research note on Wednesday, November 15th. Finally, Zacks Investment Research raised shares of WAVE Life Sciences from a sell rating to a hold rating in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $41.60.
Shares of WAVE Life Sciences (NASDAQ:WVE) opened at $38.00 on Friday. WAVE Life Sciences has a 52 week low of $15.15 and a 52 week high of $39.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.50 and a current ratio of 11.50.
In other WAVE Life Sciences news, Director Ra Capital Management, Llc acquired 423,398 shares of WAVE Life Sciences stock in a transaction that occurred on Tuesday, November 14th. The stock was acquired at an average price of $23.34 per share, with a total value of $9,882,109.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Chandra Vargeese sold 1,500 shares of WAVE Life Sciences stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $35.00, for a total transaction of $52,500.00. The disclosure for this sale can be found here. 53.00% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in WVE. American International Group Inc. raised its holdings in WAVE Life Sciences by 7.1% in the 1st quarter. American International Group Inc. now owns 4,554 shares of the company’s stock worth $125,000 after acquiring an additional 302 shares during the period. Geode Capital Management LLC raised its holdings in WAVE Life Sciences by 4.6% in the 1st quarter. Geode Capital Management LLC now owns 76,478 shares of the company’s stock worth $2,103,000 after acquiring an additional 3,397 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in WAVE Life Sciences by 6.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 30,707 shares of the company’s stock worth $845,000 after acquiring an additional 1,881 shares during the period. Strs Ohio raised its holdings in WAVE Life Sciences by 6.3% in the 2nd quarter. Strs Ohio now owns 11,900 shares of the company’s stock worth $221,000 after acquiring an additional 700 shares during the period. Finally, Rhumbline Advisers raised its holdings in WAVE Life Sciences by 62.3% in the 2nd quarter. Rhumbline Advisers now owns 12,502 shares of the company’s stock worth $233,000 after acquiring an additional 4,800 shares during the period. Hedge funds and other institutional investors own 73.74% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/12/06/wave-life-sciences-wve-rating-increased-to-strong-buy-at-bidaskclub.html.
About WAVE Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
What are top analysts saying about WAVE Life Sciences Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for WAVE Life Sciences Ltd. and related companies.